ʻO Nicotinamide adenine dinucleotide (NAD+) kahi kikowaena noiʻi o nā kānaka ʻepekema ma ka home a ma waho. Manaʻo ka hapa nui o nā kānaka ʻepekema e pili pono ana ka pae o NAD+ i nā maʻi maʻi e pili ana i ka ʻelemakule, e like me ke kanesa, ka momona, ke koko kiʻekiʻe a me ka maʻi diabetes.
ʻO ke keratinocyte carcinoma (KC) ka puʻupuʻu ʻino maʻamau i nā poʻe ʻili keʻokeʻo, me ka basal cell carcinoma (BCC) a me ka squamous cell carcinoma (cSCC). I kēia manawa, ua paʻi nā kānaka ʻepekema ʻAmelika i kahi ʻatikala kūkākūkā ma J DRUGS DERMATOL e pili ana i ka hoʻohui ʻana i nā NAD precursors NMN a me NR e hōʻemi i ka pilikia o ke kanesa keratinocyte.
Manaʻo ka mea kākau ua hōʻoia ʻia ʻo nicotinamide (NAM), ma ke ʻano he mea mua o NAD+, e Choy B a me nā kānaka ʻepekema ʻē aʻe e hōʻemi i ka nui o ka maʻi kanesa keratinocyte. Eia nō naʻe, ʻo ka nicotinamide mononucleotide (NMN) a me ka nicotinamide nucleoside (NR), ʻo ia hoʻi nā mea mua o ka synthesis NAD+, he mea hoʻohui maikaʻi paha ia e hōʻemi i ka nui o ka maʻi kanesa keratinocyte.
Hiki i ka lawelawe waha o NMN a me NR ke hoʻonui pono i ka pae o NAD +
I ka makahiki 2018, ua hōʻoia ʻo Sinclair DA a me nā kānaka ʻepekema ʻē aʻe i ka hoʻohālikelike ʻana me NAM, ʻo ka lawe ʻana i ka NMN a me NR ma ka waha e mālama i nā kānaka a me nā ʻiole ua hoʻonui i ka pae o NAD+ i loko o ke koko a me ke akepaʻa. ʻO ka hopena, ua hana maikaʻi ʻo NMN a me NR iā NAD+.
Palekana a ʻae ʻia ka NMN a me NR
Ua hoʻohana nui ʻia nā mea hoʻohui NMN a me NR i nā kānaka a me nā holoholona, a ʻaʻohe mea ʻawahia a i ʻole nā hopena koʻikoʻi i hōʻike ʻia a hiki i kēia manawa. Ua lawe kahi noiʻi lapaʻau i loko o 25 mau wahine premenopausal me ka pre-diabetes i ka mea hoʻohui NMN ma ka waha ma kahi mahele o 250 mg/lā, a ua ʻike ʻia ua hoʻonui ka NMN i ka ʻike o ka insulin ʻiʻo me ka ʻole o ka hoʻoulu ʻana i nā hanana ʻino. Ua kālele ka lua o ka noiʻi lapaʻau i ka hopena o ka mea hoʻohui NMN i ka hiki aerobic o ka poʻe holo. Ua loaʻa i nā mea komo he kanakolukumamāono he 300 mg/lā (n=12), 600 mg/lā (n=12) a i ʻole 1200 mg/lā (n=12) NMN, a ʻaʻohe hopena ʻaoʻao a i ʻole nā hanana ʻino i hōʻike ʻia. ʻOiai ʻaʻole i ʻae ka US Food and Drug Administration (FDA) i kēia mau mea ʻelua no nā mea hoʻohui meaʻai, hiki ke kūʻai maʻalahi ʻia nā mea hoʻohui NMN a me NR ma ka pūnaewele, a ua hoʻomaka ka nui o nā mea kūʻai aku e lawe iā lākou, me nā mahele mai 500mg a 1000mg/lā. ʻAʻohe hanana ʻino i loaʻa.
Ke hoʻohālikelike ʻia me NAM, hiki i ka NMN waha a me ka NR ke hoʻonui i ka pae NAD+ me ka ʻoi aku ka maikaʻi a loaʻa ka palekana a me ka hoʻomanawanui, he hoʻolālā lapaʻau kūpono ia no nā kauka ʻili e hōʻemi i ka pilikia o ke kanesa keratinocyte. Eia nō naʻe, pono mau ka nui o ka ʻikepili noiʻi lapaʻau e hōʻoia i kāna hoʻohana pono ʻana i ka mālama lapaʻau.
Nā Kuhikuhi:
[1]. Kahn B, Borrelli M, Libby T. He Loiloi Moʻolelo o Nicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside a me Nicotinamide Mononucleotide no ka Hoʻemi ʻana i ka Makaʻu o Keratinocyte Carcinoma. J Drugs Dermatol. 2022 ʻOkakopa 1;21(10):1129-1132. doi: 10.36849/JDD.6870. PMID: 36219044.
Ka manawa hoʻouna: ʻOkakopa-25-2022